How Multiomics for Precision Medicine Is Shaping the Future of Targeted Therapies
Polaris Market Research has released a new industry study estimating the global Multiomics for Precision Medicine Market at USD 1,991.6 million in 2026, with the market on track to touch USD 7,014.8 million by 2034 at a CAGR of 17.0% across the forecast window.
Industry Overview:
Demand across the market has been on an upward trajectory as biopharma developers, academic research centers, and hospital systems increasingly look beyond single-modality genomics toward integrated molecular profiling that links genomic, transcriptomic, proteomic, metabolomic, and epigenomic data with clinical outcomes. Vendors are responding by bundling instruments, reagents, software, and interpretation services into repeatable workflows rather than selling sequencing capacity alone. Large linked cohorts and structured health-data frameworks are reinforcing this momentum, and buyers are increasingly weighing analytical validity, reproducibility, and regulatory compliance alongside per-sample pricing. The shift from exploratory molecular association toward clinical-grade evidence generation is reshaping purchasing criteria across the market's key end-user groups, from academic and research institutes to pharmaceutical and biotechnology companies and clinical laboratories.
Growth Drivers & Emerging Trends:
Driver: Large, diverse, linked patient cohorts are strengthening the statistical foundation for precision-medicine models; the NIH All of Us Research Program alone now links more than 535,000 whole genomes to nearly 482,000 electronic health records, alongside proteomic and RNA-sequencing profiles.
Driver: Integrated multiomic workflows are reducing the operational friction of adding molecular layers, as vendor roadmaps increasingly connect genomics with spatial transcriptomics, single-cell analysis, and multimodal analytics under one platform.
Driver: Health-data regulation is opening more structured pathways for data reuse, with frameworks such as the European Health Data Space creating a common structure for discovering, accessing, and processing sensitive molecular and clinical datasets.
Restraints and Headwinds:
Restraint: The gap between exploratory molecular association and demonstrated clinical utility remains the primary restraint, as small cohorts, batch effects, missing information, and shifting laboratory methods can limit model reliability.
Restraint: Even as sequencing costs decline, expenses tied to sample preparation, data storage, computing, validation, and clinical interpretation keep total implementation costs high for many buyers evaluating a multiomics workflow.
Restraint: Fragmented regulatory and data-governance requirements across jurisdictions add complexity for vendors building compliant, cross-border molecular and clinical data workflows.
Key Players:
Agilent Technologies, Inc.
BD (Becton, Dickinson and Company)
Bio-Techne Corporation
Bruker Corporation
F. Hoffmann-La Roche Ltd
Illumina, Inc.
Ovation.io, Inc.
Oxford Nanopore Technologies plc
Psomagen, Inc.
QIAGEN N.V.
SOPHiA GENETICS SA
Tempus AI, Inc.
Thermo Fisher Scientific Inc.
10x Genomics, Inc.
𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐓𝐡𝐞 𝐂𝐨𝐦𝐩𝐥𝐞𝐭𝐞 𝐂𝐨𝐦𝐩𝐫𝐞𝐡𝐞𝐧𝐬𝐢𝐯𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 𝐇𝐞𝐫𝐞 :
Latest Industry Updates:
August 2026: SOPHiA GENETICS entered a global collaboration with AstraZeneca to develop, validate, and deploy companion diagnostics supporting precision oncology therapies across solid tumor and hematological indications.
August 2026: Metabolon launched the Peak Science Grant Program, giving researchers access to metabolomics analysis, bioinformatics tools, and scientific expertise.
May 2026: Roche entered a definitive agreement to acquire PathAI for up to USD 1.05 billion, combining PathAI's AI-driven digital pathology platform with Roche's companion diagnostics and oncology portfolio.
Opportunity Landscape:
Opportunity: Disease-specific longitudinal datasets tied to treatment response are emerging as a high-value opportunity, particularly where genomic data is combined with multimodal clinical information to support biomarker and trial-enrichment strategies.
Opportunity: Staged secondary-use provisions under frameworks such as the European Health Data Space are expected to open governed pathways for molecular and clinical data reuse over the coming years.
Opportunity: Single-cell and spatial resolution technologies are expanding the addressable opportunity beyond bulk profiling by revealing cellular heterogeneity, resistant cell populations, and tissue-level context relevant to treatment response.
Segmental Analysis:
By Component Outlook (Revenue, USD Million, 2021–2034)
Instruments
Consumables
Software
Services
Datasets
By Omics Type Outlook (Revenue, USD Million, 2021–2034)
Genomics
Transcriptomics
Proteomics
Metabolomics
Epigenomics
By Technology Outlook (Revenue, USD Million, 2021–2034)
Bulk Multiomics
Single-Cell Multiomics
Spatial Multiomics
Other
By Application Outlook (Revenue, USD Million, 2021–2034)
Oncology
Rare Disease
Cardiometabolic
Neurology
Other
By End User Outlook (Revenue, USD Million, 2021–2034)
Pharmaceutical & Biotechnology Companies
Academic & Research Institutes
Hospitals & Clinical Laboratories
Contract Research Organizations & Service Providers
Other
Regional Outlook:
North America: Holds the dominant regional share, supported by large public cohorts such as the NIH All of Us program, substantial biopharma activity, and established sequencing infrastructure.
Europe: The second-largest market, developing through a regulation-led model anchored by the European Health Data Space and strong genomics and translational research capabilities in Germany, France, the Netherlands, and the UK.
Asia Pacific: Forecast to register the fastest regional growth as China, Japan, Singapore, South Korea, Australia, and India scale up sequencing and digital-health infrastructure.
Latin America: Growing steadily, with Brazil and Mexico advancing through academic medical centers, diagnostic networks, and disease-focused research partnerships.
Middle East & Africa: A moderate but growing share of the global market, with Saudi Arabia, the UAE, Qatar, and South Africa developing genomics and digital-health capabilities through national genome programs.
Future Outlook:
The Multiomics for Precision Medicine Market is expected to expand as healthcare increasingly adopts data-driven approaches for disease diagnosis, treatment selection, and patient monitoring. Advances in genomics, proteomics, metabolomics, and transcriptomics are likely to strengthen the integration of multiple biological data layers.
Increasing investment in personalized healthcare, biomarker discovery, and targeted therapies may create significant growth opportunities. Improvements in sequencing technologies, bioinformatics, artificial intelligence, and data analytics are also expected to enhance the clinical applications of multiomics approaches.
Comments